Zoladex® plus tamoxifen versus zoladex® alone in pre- and peri-menopausal metastatic breast cancer
- 20 December 1990
- journal article
- clinical trial
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 37 (6) , 989-995
- https://doi.org/10.1016/0960-0760(90)90455-t
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survivalBritish Journal of Cancer, 1990
- Estrogen Deprivation in Breast CancerAnnals of the New York Academy of Sciences, 1990
- Expression of epidermal growth factor receptor in breast carcinoma.Journal of Clinical Pathology, 1990
- Ki67 immunostaining in primary breast cancer: pathological and clinical associationsBritish Journal of Cancer, 1989
- Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.Journal of Clinical Pathology, 1986
- Survival patterns in hormone treated advanced breast cancerBritish Journal of Surgery, 1986
- The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancerBritish Journal of Cancer, 1986
- Steroid receptors in early breast cancer: Value in prognosisJournal of Steroid Biochemistry, 1981
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977